| Title |
Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway
|
|---|---|
| Published in |
Drug Design, Development and Therapy, February 2014
|
| DOI | 10.2147/dddt.s53568 |
| Pubmed ID | |
| Authors |
Mengna Chi, Yan Ye, Xu Dong Zhang, Jiezhong Chen |
| Abstract |
There is currently no curative treatment for melanoma once the disease spreads beyond the original site. Although activation of the PI3K/Akt pathway resulting from genetic mutations and epigenetic deregulation of its major regulators is known to cause resistance of melanoma to therapeutic agents, including the conventional chemotherapeutic drug dacarbazine and the Food and Drug Administration-approved mutant BRAF inhibitors vemurafenib and dabrafenib, the role of extracellular stimuli of the pathway, such as insulin, in drug resistance of melanoma remains less understood. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 23% |
| Student > Bachelor | 3 | 12% |
| Professor > Associate Professor | 3 | 12% |
| Student > Ph. D. Student | 3 | 12% |
| Other | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 8 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 9 | 35% |
| Biochemistry, Genetics and Molecular Biology | 5 | 19% |
| Environmental Science | 2 | 8% |
| Immunology and Microbiology | 2 | 8% |
| Unspecified | 1 | 4% |
| Other | 5 | 19% |
| Unknown | 2 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 March 2014.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#1,416
of 2,254 outputs
Outputs of similar age
#245,645
of 323,682 outputs
Outputs of similar age from Drug Design, Development and Therapy
#13
of 21 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,682 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.